Investment decisions regarding Eledon Pharmaceuticals (ELDN) depend heavily on an individual's tolerance for clinical-stage biotechnology risk. Bullish analysts point to positive consensus "Buy" ratings, promising therapeutic pipeline results for tegoprubart in organ transplants, and strong institutional backing as reasons to buy. Conversely, conservative investors recognize the high binary risks inherent to biotech firms that lack commercialized product revenue and rely heavily on successful trial outcomes.